Syros Pharmaceuticals Inc (NASDAQ:SYRS)
| 5.58 Delayed Data As of Sep 23 |  -0.68 / -10.88%Today’s Change | 5.25 Today|||52-Week Range 51.95 | -82.88% Year-to-Date |
Latest SYRS News | Press Releases
| Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock? Sep 23 / Zacks.com - Paid Partner Content | Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug Sep 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.25 |
| Today’s open | 6.01 |
| Day’s range | 5.45 - 6.08 |
| Volume | 226,453 |
| Average volume (3 months) | 173,804 |
| Market cap | $41.6M |
Data as of 3:58pm ET, 09/23/2022
Growth & Valuation
| Earnings growth (last year) | +24.15% |
| Earnings growth (this year) | +29.81% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +55.62% |
| P/E ratio | NM |
| Price/Sales | 8.68 |
| Price/Book | 0.48 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MBOTMicrobot Medical Inc | -0.49 | -8.96% |
| --Zero Gravity Solutio... | 0.00 | 0.00% |
| LSTALisata Therapeutics ... | -0.08 | -1.68% |
| VTGNVistaGen Therapeutic... | +0.00 | +0.06% |
Data as of 3:59pm ET, 09/23/2022
Financials
| Next reporting date | November 10, 2022 |
| EPS forecast (this quarter) | -$3.99 |
| Annual revenue (last year) | $23.5M |
| Annual profit (last year) | -$86.6M |
| Net profit margin | -368.52% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
